Doc code: RCEX
Doc description: Request for Continued Examination (RCE)

Approved for use through 04/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/30EFS (03/08)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		REQU	JEST FO			N(RCE)TRANSMITTA	L				
Number 10/04s,01/2   Date 20/03-09-26 (if applicable)   10/25-1   Unit 26/15   First Named Inventor   C. Earl Woolfork   Examiner   Andrew C. Flanders   Name   Andrew C.			ı	(Submitted		-web)		T			
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV  SUBMISSION REQUIRED UNDER 37 CFR 1.114  Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendments, entered, applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendments, entered, applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendments, entered, applicant instructs of the applicant instructs of the order in which they were filed unless applicant instructs of the order in which they were filed unless applicant instructs.  Previously submitted. If final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  Representation of the arguments in the Appeal Brief or Reply Brief previously filed on 2007-12-22  The Information Disclosure Statement (IDS)  Suspension of action on the above-identified application is required under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months, Fee under 37 CFR 1.117(f) required)  Which is a Required to the Representation of the Recurrence of the Recurre		10/648,012	_	2003-08-26		1028.1		2615			
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8 1995, or to any design application. The Instruction Sheef for this form is located at WWW.USPTO.GOV  SUBMISSION REQUIRED UNDER 37 CFR 1.114  Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s).  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on 2007-12-22  Other  Information Disclosure Statement (IDS)  Affidavit(s)/ Declaration(s)  Other  MISCELLANEOUS  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		C. Earl Woolfork				Andrew C. Flanders					
Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).    Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.   Consider the arguments in the Appeal Brief or Reply Brief previously filed on	Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8										
in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).    Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.   Consider the arguments in the Appeal Brief or Reply Brief previously filed on			S	UBMISSION REQ	UIRED UNDER 37	7 CFR 1.114					
submission even if this box is not checked.    Consider the arguments in the Appeal Brief or Reply Brief previously filed on	in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s										
□ Other  □ Amendment/Reply □ Information Disclosure Statement (IDS) □ Affidavit(s)/ Declaration(s) □ Other  ■ MISCELLANEOUS □ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) □ Other  ■ FEES ■ The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. □ The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No ■ SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  ■ Patent Practitioner Signature											
Enclosed    X   Amendment/Reply	Consider the arguments in the Appeal Brief or Reply Brief previously filed on										
Amendment/Reply Information Disclosure Statement (IDS) Affidavit(s)/ Declaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	Otl	ner 									
Information Disclosure Statement (IDS)  Affidavit(s)/ Declaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	<b>X</b> Enclosed										
☐ Affidavit(s)/ Declaration(s) ☐ Other  MISCELLANEOUS  ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) ☐ Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. ☐ The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  ▼ Patent Practitioner Signature	<b>⋉</b> An	nendment/Reply									
MISCELLANEOUS  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	│	☐ Information Disclosure Statement (IDS)									
MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	Affidavit(s)/ Declaration(s)										
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)    Other	Ot	her 									
(Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)    Other	MISCELLANEOUS										
FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature							onths _				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	Other —										
The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature					FEES						
Patent Practitioner Signature	The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to										
			SIGNATUR	RE OF APPLICANT	Γ, ATTORNEY, OF	R AGENT REQUIRED					
Applicant Signature	<b>⋉</b> Patent	Practitioner Signa	ature								
	Applica	ant Signature									

Doc code: RCEX

PTO/SB/30EFS (03/08)
Doc description: Request for Continued Examination (RCE)

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Signature of Registered U.S. Patent Practitioner						
Signature	/Megan E. Lyman/	Date (YYYY-MM-DD)	2008-04-29			
Name	Megan E. Lyman	Registration Number	57054			

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.